Introduction {#s1}
============

As a leading cause of disability among adults, osteoarthritis (OA) leads to serious public health and economic burdens. Currently, treatment options for OA are generally based on symptom severity and duration, with the goals of symptom alleviation and improvement in functional status ([@B46]). Nonpharmacologic and pharmacologic strategies are used initially, while a surgical approach to OA is reserved for chronic cases when these treatments failed. Unfortunately, the currently available clinical pharmacologic treatments for OA, such as analgesia, glucocorticoids, non-steroidal anti-inflammatory drugs, and disease-modifying antirheumatic drugs, are not adequately effective ([@B8]; [@B42]; [@B47]; [@B9]; [@B5]; [@B27]; [@B29]), and generally associated with a diversity of adverse side-effects ([@B17]; [@B11]; [@B10]). For instance, analgesia does not reduce inflammation and cartilage damage ([@B5]), glucocorticoids have been reported to induce severe damages in the musculoskeletal, cardiovascular, and gastrointestinal systems ([@B11]; [@B10]), and non-steroidal anti-inflammatory drugs do not actively control arthritis progression ([@B5]). Accumulating evidence demonstrates that an ideal OA-combating agent should be able to reduce inflammation and promote cartilage regeneration safely, which has long been desired. In responding to this demand, the current strategy for disease-modifying osteoarthritis drug seeking has shifted to biologoical molecules that promote chondorgenic development and regenration.

To date, a diversity of well-known pro-chondrogenic growth factors, such as bone morphogenetic proteins (BMPs) and transforming growth factors (TGFs), have been examined for OA treatment. However, the results are not optimistic since intra-articular injection of these growth factors could even enhance the inflammatory infiltration in damaged joints ([@B2]; [@B14]; [@B19]). Meanwhile, multiple transcriptional factors that potentially suppress inflammation, such as nuclear factor of activated T cells 1 (NFATc1), NFATc2, and runt-related transcription factor 1 (RUNX1), have also be introduced in this arena against OA, while they do not hold much promise presently. For example, the function of NFATc proteins in arthritis is controversial ([@B50]; [@B33]; [@B16]).

Another possibility for fighting OA is utilizing the extracellular matrix (ECM) molecules that naturally distribute in the articular cartilage. For example, fibromodulin (FMOD) is an ECM protein with multiple keratin sulfate side-chains that belongs to the small leucine-rich proteoglycan family ([@B38]). It was first identified as a collagen-binding molecule broadly distributed in connective tissues, with particularly high expression in cartilage ([@B18]). In the past three decades, in addition to the broad attention of its effects on collagen fibrillogenesis ([@B7]), muscle development ([@B25]; [@B26]), cell reprogramming ([@B52]; [@B28]; [@B55]), angiogenesis ([@B20]; [@B53]; [@B4]), wound healing ([@B54]), and tumorigenesis ([@B39]), the involvement of FMOD in cartilage development and maintenance as well as arthritis progression, especially in temporomandibular joint (TMJ) OA, has been investigated through world-wide collaboration. Here, we review the current research investigating FMOD and arthritis, and aim to provide novel insight into the potential use of FMOD for OA management.

Spatiotemporal Distribution of FMOD During Cartilage Growth and Development {#s2}
===========================================================================

An investigation that focused on mouse glenohumeral joints demonstrated that, at 12--13 days post-coitus when the limb buds are just condensing mesenchymal cells, FMOD was not detectable at the protein level ([@B36]). Intense FMOD staining was first noticed at the surface of the scapular and humeral anlage intracellularly and pericellularly in the interzone at 14--15 days post-coitus ([@B36]). Starting from 17 days post-coitus, a strong FMOD signal was found in the ECM surrounding the chondrocytes at the surface of the joints and proliferating chondrocytes in the epiphyses of the humerus and scapula ([@B36]). Meanwhile, during postnatal maturation until adulthood, FMOD was detected throughout the ECM of the developing articular surface and the growth plate but was more abundant in articular cartilage ([@B36]). Since FMOD was associated with prechondrocytic mesenchymal cells in the interzone before joint cavitation and with developing articular chondrocytes in the maturing and young adult limbs, it has been proposed that FMOD may function in the early genesis of articular cartilage ([@B36]).

It is worth noting that FMOD shared a similar temporospatial transcriptional pattern with type II collagen in mouse knee joints during postnatal development, while *FMOD* gene expression reached the maximum level at 1 month old ([@B41]). *FMOD* transcription was restricted to chondrocytes and peaked in the proliferating zone and the early articular cartilage ([@B41]), which had been confirmed at the protein level by immunostaining ([@B36]). In mature animals, *in situ* hybridization revealed that both pericellular and interterritorial cartilage at knee joints had high *FMOD* expression with the highest intensity in the middle and deep zones of the uncalcified cartilage ([@B41]). At 6 months old, FMOD staining decreased in the uncalcified cartilage but increased in the calcified cartilage ([@B41]). FMOD was also detected in the hypertrophic chondrocytes of the secondary ossification centers and growth plate of mice at 10 days old, and transcription of *FMOD* was diminished and finally disappeared with maturation and aging of the trabecular epiphyses ([@B41]).

Structural Alteration of FMOD in Aging and Arthritis Progression {#s3}
================================================================

In addition to its spatiotemporal distribution, FMOD's structural heterogeneity was also noticed during articular cartilage growth and development. For instance, FMOD isolated from young articular cartilage carries neither α(2-6)-linked *N*-acetylneuraminic acid nor α(1-3)-linked fucose in the N-linked keratan sulfate chains ([@B23]). Meanwhile, an age-related increase has been observed in the abundance of both α(2-6)-linked *N*-acetylneuraminic acid and α(1-3)-linked fucose, but not the levels of galactose sulfation ([@B24]). Western blot showed FMOD-derived from fetal and neonatal articular cartilage (f/n-FMOD) as a diffused region with a relative molecular weight of 70--110 kDa ([@B12]; [@B40]), while FMOD-derived from mature adult (a-FMOD) was a more discrete component with a relative molecular weight of 67 kDa ([@B12]; [@B40])---larger than the FMOD core protein without post-translational modifications (46 kDa). Interestingly, digesting f/n-FMOD with keratanase II or endo β-galactosidase reduces its molecular weight to a similar level of a-FMOD ([@B12]). Thus, Roughley et al. argued that FMOD might predominantly exist in the proteoglycan form in juvenile cartilage tissues but is mainly in a glycoprotein form in the adult counterparts ([@B40]).

Interestingly, FMOD is one of the small leucine-rich proteoglycans with the most significantly increased protein fragmentation in arthritis compared with macroscopically healthy articular cartilage from the age-matched donors ([@B32]). In addition to the 59 kDa band, multiple small bands can be detected by Western blot when FMOD is isolated from articular cartilage of OA and rheumatoid arthritis patients ([@B12]; [@B40]; [@B32]; [@B44]). Moreover, when using N-glycosidase to remove the sulfate chains from FMOD isolated from arthritic articular cartilage, several protein bands with the size of 43, 40, and 27 kDa were detected ([@B12]). Therefore, arthritis progression may not only alter the degree and type of its carbohydrate substation but also lead to the breakage of the FMOD core protein.

Meanwhile, degradation of FMOD core protein was also observed in interleukin (IL)-1-challenged cartilage ([@B45]; [@B44])---a representative model that elucidates the genetic and molecular pathogenesis of inflammation-related secondary OA ([@B22]). The degradation of FMOD core protein was predominantly catalyzed by matrix metalloproteinases (MMPs) and ADAM metallopeptidases with thrombospondin type 1 motifs (ADAMTSs) ([@B21]; [@B44]). *In vitro* digestion of healthy human knee cartilage with MMP-13, ADAMTS-4, and ADAMTS-5 generated FMOD fragments of similar sizes as FMOD derived from OA cartilage without digestion ([@B44]). Notably, the fragmented FMOD is always detected by the antibody recognizing the N-terminal fragment of FMOD but not the one recognizing the C-terminal ([@B32]; [@B44]). One possible explanation is that the C-terminus is vulnerable to the fragmentation and not stably retained in the tissue, and substantially lost into the synovial fluid ([@B32]). Importantly, MMP-13 degradation of FMOD resulted in a fragment of 30 kDa, which was also detected in moderately and severely fibrillated cartilage, instead of healthy or slightly fibrillated cartilage ([@B35]). These phenomena may support the hypothesis that the sensitivity of FMOD protein fragmentation is increased along with the severity of cartilage degradation.

Lessons From FMOD Deficient Mice for OA Investigation {#s4}
=====================================================

FMOD-null (*Fmod* ^−^ *^/^* ^−^) mice have distinct knee joints in comparison with their wildtype (WT) littermates at 36 weeks old ([@B15]), accompanied by a significantly higher histological arthritis score ([@B3]). In addition, serial sections through FMOD-null mice knees showed degeneration and joint remodeling histologically. More severe incidences of degeneration occurred in the area of the tibial condyles that are uncovered by the menisci, as these sites experience the highest loading stress, resulting in considerable loss of cartilage and bone thickness ([@B15]). Moreover, the menisci of FMOD-null mice had a markedly less sharp profile with more rounded edges, similar to FMOD-null ligaments, which were also more likely to be damaged compared to WT ligaments. The area of tibial articular cartilage was even more exposed due to degenerated menisci compared to that of the WT littermates ([@B15]). Furthermore, knee joints of *Fmod* ^−^ *^/^* ^−^ mice at 80 weeks old displayed full-depth lesions of articular cartilage and clusters of cells that were not seen in the knee joints of WT littermates ([@B15]).

As biglycan (BGN) and FMOD have overlapping and possible compensatory functions in the joints ([@B43]), *BGN* and *FMOD* double-knockout (*Bgn* *^−/0^* */Fmod* *^−/−^*) mice exhibit an earlier onset of OA than *Fmod* ^−^ *^/^* ^−^ mice. *Bgn* ^−^ *^/0^* */Fmod* ^−^ *^/^* ^−^ mice presented with an abnormal gait characterized by the decreased flexibility of knee and ankle joints (dragging leg), which was observed as early as 3 weeks old. Additionally, at 3 months old, the histological arthritis score of the *Bgn* ^−^ *^/0^* */Fmod* ^−^ *^/^* ^−^ knee joints was significantly higher than that of the WT knee joints. However, the abnormal gait phenomena were observed in neither *BGN* nor *FMOD* single knockout mice ([@B3]).

Moreover, BGN and FMOD are also highly expressed in the disc and articular cartilage of the TMJ ([@B48]). *Bgn* ^−^ *^/0^* */Fmod* ^−^ *^/^* ^−^ mice developed accelerated OA accompanied by small vertical clefts in the condylar cartilage and partial disruption of the disc as compared to WT animals at 6 months old ([@B49]). At 18 months old, extensive cartilage erosion was visible in the *Bgn* ^−^ *^/0^* */Fmod* ^−^ *^/^* ^−^ mice TMJ ([@B49]).

Potential Roles of FMOD in Arthritis {#s5}
====================================

There are several hypotheses about the possible roles of FMOD in arthritis. FMOD binds to collagens ([@B31]), and fragmentation of FMOD during arthritis progression may destabilize collagen fibrils, rendering them more susceptible to tissue collagenases ([@B21]). However, such a difference between WT and FMOD-null mice may not necessarily have immediately visible effects at the ultrastructural level in adults ([@B3]).

Alternatively, FMOD may sequester TGF-β/BMP superfamily members in the ECM and thereby prevent their binding to the cellular receptors ([@B48]). For example, when treating the TMJ with BMP2, both catabolic and anabolic markers were more profoundly upregulated in the *Bgn* ^−^ *^/0^* */Fmod* ^−^ *^/^* ^−^ mice than WT animals ([@B43]). This observation suggests that BGN and FMOD could protect the condyle from BMP2-induced matric turnover ([@B43]). Additionally, the sequestration of TGF-β1 in mandibular condylar chondrocyte ECM decreased in *Bgn* ^−^ *^/0^* */Fmod* ^−^ *^/^* ^−^ mice. The overactive TGF-β1 signal transduction in *Bgn* ^−^ *^/0^* */Fmod* ^−^ *^/^* ^−^ mice accelerated both production and degradation of type II collagen and aggrecan, and subsequently led to an overall imbalance in ECM turnover that favors cartilage degradation and the onset of OA ([@B13]).

FMOD may also function as a barrier preventing cell adhesion and subsequent cartilage damage. For example, FMOD administration dramatically prevents the adhesion of polymorphonuclear neutrophils and fibroblasts on articular cartilage surfaces ([@B37]; [@B34]). This inhibition of cellular attachment may be attributed to the capability of FMOD to mask epitopes of cartilage collagen that face the joint cavity ([@B37]).

Furthermore, FMOD may participate in arthritis progression by directly manipulating inflammatory reactions. For instance, C1q and complement inhibitor factor H can directly bind to FMOD but in different regions ([@B1]). However, the deposition of the membrane attack complex and C5a release were lower in the presence of FMOD, presumably due to the formation of the FMOD-factor H complex ([@B1]). Interestingly, IL-1 only stimulates the binding of C1q, but not factor H, to the N-terminal fragment of FMOD in cartilage ([@B1]). Thus, FMOD may balance the activation of the classical complement pathway: when maintained in its intact form, FMOD silences the complement cascade by binding factor H; on the other hand, when FMOD is degraded or fragmented, as seen in OA ([@B32]; [@B44]), the N-terminal FMOD segment binds to C1q and in turn activates the complement system to eliminate pathogens and damaged cells for tissue recovery and reconstruction.

FMOD has been used as an early marker of chondrogenesis ([@B6]). The expression level of FMOD is inversely correlated with the passage number of human chondrocytes in monolayer cultivation ([@B30]). In the TMJ cartilage of 3-month-old *Bgn* ^−^ *^/0^* */Fmod* ^−^ *^/^* ^−^ mice, fewer proliferative chondrocytes were noticed in comparison to that of their WT counterparts ([@B49]). Moreover, *Bgn* ^−^ *^/0^* */Fmod* ^−^ *^/^* ^−^ mice presented with more chondrocyte apoptosis in the articular cartilage than WT mice at the same developmental stage ([@B48]). A recent study even showed that microRNA-340-5p negatively regulated OA chondrocyte proliferation while stimulating apoptosis by reducing *FMOD* expression ([@B51]). Nevertheless, the exact function of FMOD in chondrogenesis has yet to be fully uncovered.

Further Direction {#s6}
=================

As aforementioned, FMOD is a critical ECM component involved in articular cartilage development, growth, aging, and arthritis; however, the exact functions of FMOD during arthritis are still unclear. Take advantage of the development of the Cre/Lox as well as CRISPR-Cas9 recombination system, the specific functions of FMOD during arthritis progression could be deciphered in detail with tissue-specific knockout animal models. Recently, it has been reported that FMOD can be successfully produced and purified from the cell culture supernatant of stable recombinant CHO-K1 cells transfected with a plasmid harboring the human *FMOD* gene ([@B52]; [@B28]; [@B39]). Since FMOD whole protein is now easy to produce, further in-depth investigations are warranted to reveal the underlying mechanism of action of FMOD as a new generation disease-modifying osteoarthritis drug candidate. Last but not least, the plasmid- or virus-mediated expression, as well as directly synthesis, could be utilized to identify the functional sequence(s) of FMOD that regulate(s) cartilage development and pathology, which would further advance the pharmacology application of FMOD.
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